Screener
Kura Oncology KURA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -411.9%-21.9pp | -443.5%-70.4pp | -449.9%-91.4pp | -377%+148pp | -390%+329pp | |
| Net margin | -384.3%-34.3pp | -411.2%-77.6pp | -412.9%-90.1pp | -340.9%+148pp | -350%+325pp | |
| Returns | ||||||
| Return on equity | -167.7%-117pp | -124.7%-82.9pp | -94.8%-51.9pp | -65.1%-18.8pp | -51.1%-11.8pp | |
| Return on invested capital | -259%-194pp | -149.3%-99.3pp | -241.7%-175pp | -86%-33.6pp | -64.6%-19.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.7×-1.4× | 6.1×-1.9× | 6.1×-3.4× | 5.1×-6.4× | 6.2×-8.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×+0.4× | 0.2×+0.2× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $0.55-84.4% | $1.22-70.8% | $1.99-58.6% | $2.77-43.2% | $3.49-35.2% | |
| Valuation | ||||||
| Market capitalization | $947.43M+19.4% | $718.12M+34.7% | $904.11M+33.5% | $768.16M-54.6% | $517.72M-70.0% | |
| Price / sales | 12.3×-0.2× | 10×+0.2× | 13.4×+0.8× | 12.1×-29.8× | 9.2×-54.9× | |
| Price / book | 19.6×+16.3× | 6.7×+5.2× | 5.2×+3.6× | 3.2×-0.8× | 1.7×-2.0× |
FAQ
- Where do Kura Oncology's ratios come from?
- Every ratio is computed from Kura Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
